Ultragenyx Pharmaceutical Inc
RARE33.760USD
+0.235+0.70%
終値 11/26, 16:00（ET）15分遅れの株価
3.26B時価総額
損失額直近12ヶ月PER
詳細情報 Ultragenyx Pharmaceutical Inc 企業名
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.
Ultragenyx Pharmaceutical Incの企業情報
企業コードRARE
会社名Ultragenyx Pharmaceutical Inc
上場日Jan 31, 2014
最高経営責任者「CEO」Dr. Emil D. Kakkis, M.D., Ph.D.
従業員数1294
証券種類Ordinary Share
決算期末Jan 31
本社所在地60 Leveroni Ct
都市NOVATO
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号94949
電話番号14154838800
ウェブサイトhttps://www.ultragenyx.com/
企業コードRARE
上場日Jan 31, 2014
最高経営責任者「CEO」Dr. Emil D. Kakkis, M.D., Ph.D.
Ultragenyx Pharmaceutical Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.69M
-1.17%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
107.20K
+41.78%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
41.99K
+83.47%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
27.34K
+26.57%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
27.34K
+26.57%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
20.59K
+38.64%
Dr. Amrit Ray, M.D.
Dr. Amrit Ray, M.D.
Independent Director
Independent Director
18.02K
+46.74%
Mr. Howard Horn
Mr. Howard Horn
Chief Financial Officer, Executive Vice President, Corporate Strategy
Chief Financial Officer, Executive Vice President, Corporate Strategy
7.75K
-50.61%
Mr. John R. Pinion, II
Mr. John R. Pinion, II
Chief Quality Officer, Executive Vice President - Translational Sciences
Chief Quality Officer, Executive Vice President - Translational Sciences
--
--
Mr. Eric Olson
Mr. Eric Olson
Chief Business Officer, Executive Vice President
Chief Business Officer, Executive Vice President
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.69M
-1.17%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
107.20K
+41.78%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
41.99K
+83.47%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
27.34K
+26.57%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
27.34K
+26.57%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
20.59K
+38.64%
収益内訳
通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
事業別USD
会社名
収益
比率
Crysvita royalty revenue
85.68M
51.46%
Crysvita
34.73M
20.86%
Dojolvi
23.21M
13.94%
Evkeeza
14.57M
8.75%
Mepsevii
8.31M
4.99%
地域別USD
会社名
収益
比率
North America
102.93M
61.82%
Latin America
32.97M
19.80%
Europe
26.40M
15.86%
Japan
4.20M
2.52%
事業別
地域別
事業別USD
会社名
収益
比率
Crysvita royalty revenue
85.68M
51.46%
Crysvita
34.73M
20.86%
Dojolvi
23.21M
13.94%
Evkeeza
14.57M
8.75%
Mepsevii
8.31M
4.99%
株主
更新時刻: Tue, Nov 18
更新時刻: Tue, Nov 18
株主統計
種類
株主統計
株主統計
比率
The Vanguard Group, Inc.
10.48%
BlackRock Institutional Trust Company, N.A.
5.26%
Fidelity Management & Research Company LLC
4.07%
Sands Capital Management, LLC
3.91%
State Street Investment Management (US)
3.83%
他の
72.46%
株主統計
株主統計
比率
The Vanguard Group, Inc.
10.48%
BlackRock Institutional Trust Company, N.A.
5.26%
Fidelity Management & Research Company LLC
4.07%
Sands Capital Management, LLC
3.91%
State Street Investment Management (US)
3.83%
他の
72.46%
種類
株主統計
比率
Investment Advisor
51.75%
Investment Advisor/Hedge Fund
31.58%
Hedge Fund
15.20%
Individual Investor
3.48%
Research Firm
2.31%
Sovereign Wealth Fund
1.02%
Private Equity
1.02%
Pension Fund
0.52%
Bank and Trust
0.40%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
640
97.34M
100.90%
-3.53M
2025Q2
635
97.48M
101.32%
-2.63M
2025Q1
652
96.83M
102.45%
-3.19M
2024Q4
645
94.29M
102.32%
-4.54M
2024Q3
633
93.51M
101.49%
-6.93M
2024Q2
618
95.17M
101.90%
+3.05M
2024Q1
605
86.17M
101.67%
-4.74M
2023Q4
588
86.44M
105.27%
+5.64M
2023Q3
574
75.90M
106.07%
-3.60M
2023Q2
591
75.05M
105.07%
-3.13M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
The Vanguard Group, Inc.
10.19M
10.58%
+217.20K
+2.18%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.02M
5.21%
+106.89K
+2.18%
Jun 30, 2025
Fidelity Management & Research Company LLC
2.27M
2.36%
+1.89M
+495.36%
Jun 30, 2025
Sands Capital Management, LLC
3.94M
4.09%
-220.08K
-5.29%
Jun 30, 2025
State Street Investment Management (US)
2.57M
2.67%
-46.25K
-1.77%
Jun 30, 2025
RTW Investments L.P.
1.71M
1.77%
--
--
Jun 30, 2025
JP Morgan Asset Management
2.60M
2.7%
+2.56M
+5502.04%
Jun 30, 2025
Baker Bros. Advisors LP
2.77M
2.88%
+1.20M
+75.92%
Jun 30, 2025
Kakkis (Emil D)
2.69M
2.79%
-31.78K
-1.17%
Mar 07, 2025
詳細を見る
関連ETF
更新時刻: Thu, Nov 6
更新時刻: Thu, Nov 6
銘柄名
比率
Motley Fool Small-Cap Growth ETF
3.15%
Global X Genomics & Biotechnology ETF
2.87%
Franklin Genomic Advancements ETF
1.35%
Virtus LifeSci Biotech Products ETF
1.27%
SPDR S&P Biotech ETF
1.21%
WisdomTree BioRevolution Fund
0.88%
Touchstone Sands Capital US Select Growth ETF
0.8%
Direxion Daily S&P Biotech Bull 3X Shares
0.63%
First Trust Multi-Manager Large Growth ETF
0.55%
Goldman Sachs Future Health Care Equity ETF
0.5%
詳細を見る
Motley Fool Small-Cap Growth ETF
比率3.15%
Global X Genomics & Biotechnology ETF
比率2.87%
Franklin Genomic Advancements ETF
比率1.35%
Virtus LifeSci Biotech Products ETF
比率1.27%
SPDR S&P Biotech ETF
比率1.21%
WisdomTree BioRevolution Fund
比率0.88%
Touchstone Sands Capital US Select Growth ETF
比率0.8%
Direxion Daily S&P Biotech Bull 3X Shares
比率0.63%
First Trust Multi-Manager Large Growth ETF
比率0.55%
Goldman Sachs Future Health Care Equity ETF
比率0.5%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
よくある質問
Ultragenyx Pharmaceutical Incの上位5名の株主は誰ですか？
Ultragenyx Pharmaceutical Incの上位5名の株主は以下のとおりです。
The Vanguard Group, Inc.は10.19M株を保有しており、これは全体の10.58%に相当します。
BlackRock Institutional Trust Company, N.A.は5.02M株を保有しており、これは全体の5.21%に相当します。
Fidelity Management & Research Company LLCは2.27M株を保有しており、これは全体の2.36%に相当します。
Sands Capital Management, LLCは3.94M株を保有しており、これは全体の4.09%に相当します。
State Street Investment Management (US)は2.57M株を保有しており、これは全体の2.67%に相当します。
The Vanguard Group, Inc.は10.19M株を保有しており、これは全体の10.58%に相当します。
BlackRock Institutional Trust Company, N.A.は5.02M株を保有しており、これは全体の5.21%に相当します。
Fidelity Management & Research Company LLCは2.27M株を保有しており、これは全体の2.36%に相当します。
Sands Capital Management, LLCは3.94M株を保有しており、これは全体の4.09%に相当します。
State Street Investment Management (US)は2.57M株を保有しており、これは全体の2.67%に相当します。
Ultragenyx Pharmaceutical Incの株主タイプ上位3種は何ですか？
Ultragenyx Pharmaceutical Incの株主タイプ上位3種は、
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Fidelity Management & Research Company LLC
Ultragenyx Pharmaceutical Inc（RARE）の株式を保有している機関の数はいくつですか？
2025Q3時点で、Ultragenyx Pharmaceutical Incの株式を保有している機関は640社あり、保有株式の総市場価値は約97.34Mで、全体の100.90%を占めています。2025Q2と比較して、機関の持ち株は-0.43%増加しています。
Ultragenyx Pharmaceutical Incの最大の収益源は何ですか？
FY2025Q2において、Crysvita royalty revenue部門がUltragenyx Pharmaceutical Incにとって最大の収益を生み出しており、その金額は85.68Mで、全収益の51.46%を占めています。
